Sort by
Items per page

Send to

Choose Destination

Search results

Items: 11


Immunotherapy with HDC/IL-2 may be clinically efficacious in acute myeloid leukemia of normal karyotype.

Nilsson MS, Hallner A, Brune M, Nilsson S, Thorén FB, Martner A, Hellstrand K.

Hum Vaccin Immunother. 2019 Jul 24:1-3. doi: 10.1080/21645515.2019.1636598. [Epub ahead of print]


The HLA-B -21 dimorphism impacts on NK cell education and clinical outcome of immunotherapy in acute myeloid leukemia.

Hallner A, Bernson E, Hussein BA, Ewald Sander F, Brune M, Aurelius J, Martner A, Hellstrand K, Thorén FB.

Blood. 2019 Mar 28;133(13):1479-1488. doi: 10.1182/blood-2018-09-874990. Epub 2019 Jan 15.


NOX2 inhibition reduces oxidative stress and prolongs survival in murine KRAS-induced myeloproliferative disease.

Aydin E, Hallner A, Grauers Wiktorin H, Staffas A, Hellstrand K, Martner A.

Oncogene. 2019 Feb;38(9):1534-1543. doi: 10.1038/s41388-018-0528-1. Epub 2018 Oct 15.


Cytomegalovirus Serostatus Affects Autoreactive NK Cells and Outcomes of IL2-Based Immunotherapy in Acute Myeloid Leukemia.

Bernson E, Hallner A, Sander FE, Nicklasson M, Nilsson MS, Christenson K, Aydin E, Liljeqvist JÅ, Brune M, Foà R, Aurelius J, Martner A, Hellstrand K, Thorén FB.

Cancer Immunol Res. 2018 Sep;6(9):1110-1119. doi: 10.1158/2326-6066.CIR-17-0711. Epub 2018 Jul 6.


Determinants for Effective ALECSAT Immunotherapy Treatment on Autologous Patient-Derived Glioblastoma Stem Cells.

Wenger A, Werlenius K, Hallner A, Thorén FB, Farahmand D, Tisell M, Smits A, Rydenhag B, Jakola AS, Carén H.

Neoplasia. 2018 Jan;20(1):25-31. doi: 10.1016/j.neo.2017.10.006. Epub 2017 Dec 1.


Impact of killer-immunoglobulin-like receptor and human leukocyte antigen genotypes on the efficacy of immunotherapy in acute myeloid leukemia.

Bernson E, Hallner A, Sander FE, Wilsson O, Werlenius O, Rydström A, Kiffin R, Brune M, Foà R, Aurelius J, Martner A, Hellstrand K, Thorén FB.

Leukemia. 2017 Dec;31(12):2552-2559. doi: 10.1038/leu.2017.151. Epub 2017 May 22.


NOX2-dependent immunosuppression in chronic myelomonocytic leukemia.

Aurelius J, Hallner A, Werlenius O, Riise R, Möllgård L, Brune M, Hansson M, Martner A, Thorén FB, Hellstrand K.

J Leukoc Biol. 2017 Aug;102(2):459-466. doi: 10.1189/jlb.5VMA1116-454R. Epub 2017 Mar 14.


Dynamics of myeloid cell populations during relapse-preventive immunotherapy in acute myeloid leukemia.

Rydström A, Hallner A, Aurelius J, Sander FE, Bernson E, Kiffin R, Thoren FB, Hellstrand K, Martner A.

J Leukoc Biol. 2017 Aug;102(2):467-474. doi: 10.1189/jlb.5VMA1116-455R. Epub 2017 Feb 24.


Reactive oxygen species induced by therapeutic CD20 antibodies inhibit natural killer cell-mediated antibody-dependent cellular cytotoxicity against primary CLL cells.

Werlenius O, Aurelius J, Hallner A, Akhiani AA, Simpanen M, Martner A, Andersson PO, Hellstrand K, Thorén FB.

Oncotarget. 2016 May 31;7(22):32046-53. doi: 10.18632/oncotarget.8769.


Immunotherapy with histamine dihydrochloride and low-dose interleukin-2 favors sustained lymphocyte recovery in acute myeloid leukemia.

Hallner A, Aurelius J, Thorén FB, Sander FE, Brune M, Hellstrand K, Martner A.

Eur J Haematol. 2015 Mar;94(3):279-80. doi: 10.1111/ejh.12454. Epub 2014 Nov 21. No abstract available. Erratum in: Eur J Haematol. 2019 Jan;102(1):99.


The regenerative capacity of the pancreas in duct-ligated rats.

Hultquist GT, Karlsson U, Hallner AC.

Exp Pathol (Jena). 1979;17(1):44-52. No abstract available.


Supplemental Content

Loading ...
Support Center